Inovio outlines late Q4 2027 cash runway as it targets VOCERYQ launch and Europe filing by year-end 2026 (NASDAQ:INO)
· seekingalpha.com
Inovio wins FDA accelerated approval for VOCERYQ and targets Q1 2027 field deployment; its $80.5 million offering helps extend runway into late Q4 2027.
Earnings Call Insights Inovio outlines late Q4 2027 cash runway as it targets VOCERYQ launch and Europe filing by year-end 2026 Nov 10, 2026, 8:22 PM ET Inovio ...